Fenspiride

DB08979InvestigationalSmall molecule

Fenspiride is an oxazolidinone spiro compound with antispasmodic and bronchodilator effects used in the treatment of ENT and respiratory diseases. It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance...

Mechanism: Pharmacologically active on cGMP-specific 3',5'-cyclic phosphodiesterase, Histamine H1 receptor, and Phosphodiesterase 3
Curator reviewed
Formula / weight: C₁₅H₂₀N₂O₂ · 260.3315 g/mol (avg)

Resolves to

Compound

UNIIS983QC7HKMCAS5053-06-5ChEMBLCHEMBL576127ChEBI94558PubChem3344

Clinical / RWD

RxNorm4335ATCR03BX01ATCR03DX03

Structure

InChIKeyFVNFBBAOMBJTST-UHFFFAOYSA-NSMILESO=C1NCC2(CCN(CCC3=CC=CC=C3)CC2)O1

Targets

O76074PDE5AP35367HRH1

What you can answer from here — as of September 23, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

18Structured indicationsCondition, population, route and combination as fields, not prose

2ContraindicationsEach with its own population and attribute set

12Marketed productsAcross 2 countries and 6 labellers

2ATC codesIncluding every combination product, plus 6 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fenspiride, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In